Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993 Apr;43(4):662-7.
doi: 10.1212/wnl.43.4.662.

Interferon beta-1b Is Effective in Relapsing-Remitting Multiple Sclerosis. II. MRI Analysis Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

Affiliations
Clinical Trial

Interferon beta-1b Is Effective in Relapsing-Remitting Multiple Sclerosis. II. MRI Analysis Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

D W Paty et al. Neurology. .

Abstract

We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical results are presented in the preceding companion paper. Baseline MRI characteristics were the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans (median 80% reduction, p = 0.0082) and appearance of new lesions. In addition, there was an equally significant reduction in MRI-detected burden of disease in the treatment as compared with placebo groups (mean group difference of 23%, p = 0.001). These results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients.

Comment in

Similar articles

See all similar articles

Cited by 227 articles

See all "Cited by" articles

Substances

LinkOut - more resources

Feedback